Progress in preventive therapy of neuromyelitis optica spectrum disorder attack and pharmaceutical care for one pediatric patient
FANG Ling-zhi
CHEN Chao-yang
MA Ling-yue
DONG Zhan-jun
ZHOU Yan
WU Ye
ZHOU Ying
CUI Yi-min
Abstract：Objective:To summarize the drug selection for preventive therapy of neuromyelitis optica spectrum disorder (NMOSD) attack so as to improve the understanding of the preventive therapy for the disease and provide reference for making better clinical choice.Methods:The related literatures in recent years about NMOSD attack's preventive therapy were searched through PubMed,then the choice of immunosuppressants for the disease was analyzed and concluded.The choice of immunosuppressants for one pediatric patient with NMOSD was discussed.Results:The authors think the most effective option for preventive therapy of NMOSD attack is rituximab,followed by mycophenolate,and then azathioprine.If the therapeutic effect is poor with the above-mentioned three immunosuppressants,the second-line drugs such as methotrexate,mitoxantrone or cyclophosphamide,etc.,are suggested to be used.For the pediatric patient with NMOSD in our hospital,the pharmacists recommended the physicians to select mycophenolate mofetil and conducted pharmaceutical care after drug administration.Conclusion:The individualized therapy suggestion given by the clinical pharmacist for the pediatric patient promoted the safety,effectiveness and rationality of clinical therapy.
Keywords：neuromyelitis optica spectrum disorderimmunosuppressantrituximabmycophenolateazathioprinepharmaceutical care
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：3( 957-959 )